SYRE

Spyre Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Spyre Therapeutics sales and earnings growth
SYRE Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 37.74%
  • FCF Y/Y↓ -7.52%
Spyre Therapeutics gross and profit margin trends
SYRE Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -33.50%
Spyre Therapeutics net debt vs free cash flow
SYRE Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Spyre Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗